Product matrix2
AI-assisted product illustrations · Product information on detail pages
2026 Q2 · 2026-06-30
Financial visuals and sources
Revenue, profit, cash measures and issuer outlook are presented separately. Subsequent events and unresolved scope differences are identified in the report.
Read full visuals, data and sources (Chinese) ↗Visual research edition · integrated September 13, 2026. Each source retains its reporting period and review date. Not investment advice.
Coverage Timeline2
Following since 2025.05- 20252025.07.013 min
The Drugmaker vs. the Platform: Novo Nordisk Dumps Hims & Hers
On the 23rd, Novo Nordisk terminated its partnership with Hims & Hers Health, citing "deceptive marketing" practices.
- 2025.05.146 min
HIMS: Blowout Q1 2025 Earnings vs. Trump's Drug Price Cuts
Hims & Hers Health, Inc. (HIMS) reported Q1 2025 revenue up 111% YoY, with subscribers and profitability surging. Meanwhile, Trump's executive orders to slash US drug prices could reshape HIMS's cost structure and competitive landscape. This analysis dives into the numbers and the policy impact.
